Page 14 - Cardiovascular Sciences News Today

Millions of people worldwide could benefit from the drug that can potentially treat a severe form of fatty liver disease.

Health News - Despite the success of vaccines for preventing COVID-19, and of drugs for treating the disease, outcomes for severely ill patients admitted to the hospital remains poor. Identifying new therapies for severe COVID-19 remains a high priority and one in which Vanderbilt University Medical Center is taking a leading role. A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin ...

Washington, Apr 11 (Prensa Latina) A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests.

Nonalcoholic steatohepatitis, or NASH, is a severe liver disease and impacts millions of people

A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates -; bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests.

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics Agreement grants Freeline rights to develop and commercialise AAV gene therapies using

Investegate announcements from Forcefield Therapeutics, Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics

Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients

23.03.2023 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today released its ...